Sweden's Biosergen Q4 net loss widens as BSG005 advances

Biosergen AB

10/02/2026 07:38

Overview

Biotechnology firm's Q4 net loss widened as it advances BSG005 program

Company held successful pre-IND meeting with FDA for BSG005

Executed reverse share split of 1:100 in December 2025

Outlook

Company aims to release new BSG005 drug batch for clinical trials

Biosergen evaluates financing options amid extended manufacturing timelines

Company plans to resume trials in India with local partners

Result Drivers

BSG005 MANUFACTURING - Co focused on finalizing drug supply and strengthening manufacturing process for BSG005

FDA GUIDANCE - Successful pre-IND meeting with FDA provided clear regulatory guidance for BSG005

FINANCIAL CHALLENGES - Co acknowledged need to strengthen financial position amid extended timelines

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-SEK 5.31
Q4 Net Income
-SEK 12.46 mln
Q4 EBITDA
-SEK 12.49 mln


Analyst Coverage

Wall Street's median 12-month price target for Biosergen AB is SEK150.00, about 244% above its February 9 closing price of SEK43.60

Press Release: ID:nWkrbJtGs7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)